Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population

Fundamental and Clinical Pharmacology

Volumn 21, Issue 4, 2007, Pages 379-386

  Hilli, Johanna ^a   Rane, Anders ^b   Lundgren, Stefan ^b   Bertilsson, Leif ^b   Laine, Kari ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ABCB1; CYP3A5; Finland; Finnish; Genotype; Polymorphism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; GLYCOPROTEIN P;

ADULT; AGED; ALLELE; ARTICLE; ASIA; BLOOD ANALYSIS; CAUCASIAN; DATA ANALYSIS; DNA DETERMINATION; DRUG METABOLISM; FEMALE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 34447560176     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00494.x     Document Type: Article

References (39)

1. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. (2004) 25 193 200.
2. Aklillu E., Carrillo J.A., Makonnen E. et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. (2003) 64 659 669.
3. Home Page of the Human Cytochrome P 450 (CYP) Allele Nomenclature Committee. Ingelman-Sundberg M, Daly AK, Nebert DW, (Eds.) URL http://www.cypalleles.ki.se [accessed on 25 April 2007].
4. Nordmark A., Lundgren S., Ask B., Granath F., Rane A. The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br. J. Clin. Pharmacol. (2002) 54 504 510.
5. Dai D., Zeldin D.C., Blaisdell J.A. et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 11 597 607.
6. Lundblad M.S., Stark K., Eliasson E., Oliw E., Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem. Biophys. Res. Commun. (2005) 327 1052 1057.
7. Goldstein J.A. Clinical relevance of genetic polymorphism in the human CYP2C subfamily. Br. J. Clin. Pharmacol. (2001) 52 349 355.
8. Furuya H., Fernandez-Salguero P., Gregory W. et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics (1995) 5 389 392.
9. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353 717 719.
10. Lindh J.D., Lundgren S., Holm L., Alfredsson L., Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. (2005) 78 540 550.
11. Chang M., Dahl M.-L., Tybring G., Götharson E., Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 5 358 363.
12. Allabi A.C., Gala J.L., Desager J.P., Heusterspreute M., Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol. (2003) 56 653 657.
13. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286 487 491.
14. Kuehl P., Zhang J., Lin Y. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27 383 391.
15. Huang Z., Guengerich F.P., Kaminsky L.S. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis (1998) 19 867 872.
16. Hustert E., Haberl M., Burk O. et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 11 773 779.
17. Ozawa S., Soyama A., Saeki M. et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. (2004) 19 83 95.
18. Hoffmeyer S., Burk O., von Richter O. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. U. S. A. (2000) 97 3473 3478.
19. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75 13 33.
20. Kallio J., Lindberg R., Huupponen R., Iisalo E. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br. J. Clin. Pharmacol. (1988) 26 791 795.
21. Skarke C., Kirchhof A., Geisslinger G., Lötsch J. Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur. J. Clin. Pharmacol. (2005) 61 887 892.
22. Sachse C., Bhambra U., Smith G. et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol. (2003) 55 68 76.
23. Sachse C., Brockmöller J., Bauer S., Roots I. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. (1999) 47 445 449.
24. Yasar U., Lundgren S., Eliasson E. et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. (2002) 299 25 28.
25. Bahadur N., Leathart J.B., Mutch E. et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. (2002) 64 1579 1589.
26. Aithal G.P., Day C.P., Leathart J.B., Daly A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics (2000) 10 511 518.
27. Pedersen R.S., Verstuyft C., Becquemont L., Jaillon P., Brøsen K. Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Denmark. Basic Clin. Pharmacol. Toxicol. (2004) 94 151 152.
28. Yasar U., Eliasson E., Dahl M.L., Johansson I., Ingelman-Sundberg M., Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. (1999) 254 628 631.
29. Griese E.U., Ilett K.F., Kitteringham N.R. et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics (2001) 11 69 76.
30. Aynacioglu A.S., Sachse C., Bozkurt A. et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. (1999) 66 185 192.
31. Gervasini G., Vizcaino S., Gasiba C., Carrillo J.A., Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther. Drug Monit. (2005) 27 819 821.
32. Furuno T., Landi M.T., Ceroni M. et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics (2002) 12 529 534.
33. Schaeffeler E., Eichelbaum M., Brinkmann U. et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 358 383 384.
34. Bernal M.L., Sinues B., Fanlo A., Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. (2003) 25 107 111.
35. Kivistö K.T., Niemi M., Schaeffeler E. et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am. J. Pharmacogenomics (2005) 5 191 195.
36. Grogan W.M., Phillips V.M., Schuetz E.G., Guzelian P.S., Watlington C.O. Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. Am. J. Physiol. (1990) 258 C480 C488.
37. Morris D.J., Latif S.A., Rokaw M.D., Watlington C.O., Johnson J.P. A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am. J. Physiol. (1998) 274 C1245 C1252.
38. Kreutz R., Zuurman M., Kain S., Bolbrinker J., de Jong P.E., Navis G. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet. Genomics (2005) 15 831 837.
39. McKean C., Tang L., Tang M. et al. Comparative acute and combinative toxicity of aflatoxin B (1) and fumonisin B (1) in animals and human cells. Food Chem. Toxicol. (2006) 44 868 876.